Sign in
CompletedPhase 2/3

Low Dose Versus High Dose Methylene Blue in Septic Patients

Key facts

Who runs it
National Cancer Institute, Egypt
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
90 people enrolled
Started
1 Aug 2023
Ended
15 May 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Normal saline
  • Methylene Blue low dose
  • Methylene Blue high dose
Record updated
5 July 2024

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients aged ≥ 18 years and ≤ 65 with septic shock as defined by Sepsis-3 criteria (confirmed infection, requiring vasopressor to maintain a mean arterial blood pressure (MAP) ≥ 65 mmHg, and serum lactate > 2 mmol/L after adequate fluid resuscitation), and requiring mechanical ventilation

Who cannot take part

  • recent intake (4-weeks) of selective serotonin re-uptake inhibitors or MAOi
  • myocardial infarction or cerebrovascular accident within the last 3 months
  • known allergy to MB or food dyes and the use of nitrates within the last 3 days
  • severe lung , liver or kidney disease (creatinine >3.5 mg/dL)
  • glucose 6-phosphate-dehydrogenase deficiency
  • pregnancy
  • more than 24 hrs since initiation of norepinephrine
  • other causes of shock than sepsis
  • refusal of the patient guardian to participate

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main aim of this study is to examine the various effects of continuous methylene blue infusion in septic cancer patients and to compare it with the traditional infusion of noradrenaline in such patients .

The 3 groups in the trial

  • Normal salineExisting treatment, for comparison

    30 patients will receive placebo of 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of Nacl for 72 hours.

    Treatment: Methylene Blue low dose and Methylene Blue high dose

  • methylene blue low doseExisting treatment, for comparison

    30 patients will receive a bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.

    Treatment: Normal saline and Methylene Blue high dose

  • methylene blue high doseExisting treatment, for comparison

    30 patients will receive a bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.

    Treatment: Normal saline and Methylene Blue low dose

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparative Study Between High and Low Dose Methylene Blue Infusion in Septic Cancer Patients. A Randomized Blinded Controlled Study
Publications
Record updated
5 July 2024